Ashland Inc. (ASH) Q4 2024 Earnings Call Transcript
Ashland Inc. (NYSE:ASH ) Q4 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants William Whitaker - VP, Finance and Director, IR Guillermo Novo - Chair and CEO Kevin Willis - SVP and CFO Alessandra Faccin - SVP and GM, Life Sciences and Intermediates Jim Minicucci - SVP and GM, Personal Care Dago Caceres - SVP and GM, Specialty Additives Conference Call Participants Michael Sison - Wells Fargo James Cannon - UBS John Roberts - Mizuho Mike Harrison - Seaport Research Partners Operator Thank you for standing by. My name is Hermione and I will be your conference operator today.
Ashland (ASH) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Ashland (ASH) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Ashland (ASH) Q4 Earnings Lag Estimates
Ashland (ASH) came out with quarterly earnings of $1.26 per share, missing the Zacks Consensus Estimate of $1.33 per share. This compares to earnings of $0.41 per share a year ago.
Unveiling Ashland (ASH) Q4 Outlook: Wall Street Estimates for Key Metrics
Evaluate the expected performance of Ashland (ASH) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Ashland (ASH) Reports Next Week: Wall Street Expects Earnings Growth
Ashland (ASH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ashland Boosts the Application of Super Wetting Technology
ASH's technology enables agricultural retailers to increase crop yield, facilitating organic growth.
Ashland Wraps Up Nutraceuticals Business Sale to Turnspire Affiliate
ASH's nutraceuticals business provides nutrition product producers with a diverse selection of active ingredients and formulation aids.
Here's Why Ashland (ASH) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ASH vs. NVZMY: Which Stock Should Value Investors Buy Now?
Investors with an interest in Chemical - Specialty stocks have likely encountered both Ashland (ASH) and Novozymes A/S (NVZMY). But which of these two stocks offers value investors a better bang for their buck right now?
Why Ashland (ASH) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Ashland's (ASH) Earnings Beat Estimates in Q3, Sales Lag
Ashland's (ASH) Q3 sales are adversely impacted by reduced Life Sciences volumes and weaker pricing.
Here's What Key Metrics Tell Us About Ashland (ASH) Q3 Earnings
Although the revenue and EPS for Ashland (ASH) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
